5 Drugs Stocks Driving The Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 20 points (-0.1%) at 15,298 as of Wednesday, June 19, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 2,604 issues advancing vs. 474 declining with 57 unchanged.

The Drugs industry currently sits down 0.25 versus the S&P 500, which is down 0.17. Top gainers within the industry include Vertex Pharmaceuticals ( VRTX), up 0.5%, and Merck ( MRK), up 0.8%. On the negative front, top decliners within the industry include Abbott Laboratories ( ABT), down 1.23, Celgene Corporation ( CELG), down 1.08, Biogen Idec ( BIIB), down 1.24, Novo Nordisk A/S ( NVO), down 0.93 and Eli Lilly and Company ( LLY), down 0.67.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Grifols ( GRFS) is one of the companies pushing the Drugs industry higher today. As of noon trading, Grifols is up $0.37 (1.40) to $26.83 on average volume Thus far, 439,532 shares of Grifols exchanged hands as compared to its average daily volume of 594,900 shares. The stock has ranged in price between $26.30-$26.85 after having opened the day at $26.53 as compared to the previous trading day's close of $26.46.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $14.8 billion and is part of the health care sector. Shares are up 2.5% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, MannKind Corporation ( MNKD) is up $0.52 (7.95) to $7.13 on heavy volume Thus far, 7.4 million shares of MannKind Corporation exchanged hands as compared to its average daily volume of 7.1 million shares. The stock has ranged in price between $6.65-$7.25 after having opened the day at $6.78 as compared to the previous trading day's close of $6.60.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. MannKind Corporation has a market cap of $2.2 billion and is part of the health care sector. Shares are up 226.4% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate MannKind Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates MannKind Corporation as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and weak operating cash flow. Get the full MannKind Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Alexion Pharmaceuticals ( ALXN) is up $1.25 (1.35) to $93.64 on heavy volume Thus far, 1.7 million shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $93.64-$95.85 after having opened the day at $93.79 as compared to the previous trading day's close of $92.39.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $17.8 billion and is part of the health care sector. The company has a P/E ratio of 62.5, above the S&P 500 P/E ratio of 17.7. Shares are down 1.4% year to date as of the close of trading on Tuesday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Alexion Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Valeant Pharmaceuticals International ( VRX) is up $0.99 (1.15) to $86.85 on heavy volume Thus far, 5.3 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $85.62-$87.10 after having opened the day at $86.20 as compared to the previous trading day's close of $85.86.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $25.9 billion and is part of the health care sector. Shares are up 43.7% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Pfizer ( PFE) is up $0.23 (0.78) to $29.63 on heavy volume Thus far, 50.3 million shares of Pfizer exchanged hands as compared to its average daily volume of 45.4 million shares. The stock has ranged in price between $29.23-$29.66 after having opened the day at $29.37 as compared to the previous trading day's close of $29.40.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $206.0 billion and is part of the health care sector. The company has a P/E ratio of 20.7, above the S&P 500 P/E ratio of 17.7. Shares are up 17.2% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Pfizer Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Markets Push Higher Following Fed Chair's First Testimony on Capitol Hill

Markets Push Higher Following Fed Chair's First Testimony on Capitol Hill

Nasdaq Hits Intraday High Despite Netflix's Whiff

Nasdaq Hits Intraday High Despite Netflix's Whiff

Goldman Shares Slump on Outlook Worries as Profit Jumps 40%

Goldman Shares Slump on Outlook Worries as Profit Jumps 40%

UnitedHealth's Beat Wasn't Clean, Says Analysts

UnitedHealth's Beat Wasn't Clean, Says Analysts

Depositors Stiffed as Bank of America Reaps Windfall From Taxes, Rates

Depositors Stiffed as Bank of America Reaps Windfall From Taxes, Rates